PD21-10 A RANDOMIZED CONTROLLED TRIAL FOR PAIN CONTROL IN LAPAROSCOPIC UROLOGIC SURGERY: 0.25% BUPIVACAINE VERSUS LONG-ACTING LIPOSOMAL BUPIVACAINE

Abstract

You have accessJournal of UrologyTechnology & Instruments: Laparoscopy and Robotics: Benign Disease1 Apr 2015PD21-10 A RANDOMIZED CONTROLLED TRIAL FOR PAIN CONTROL IN LAPAROSCOPIC UROLOGIC SURGERY: 0.25% BUPIVACAINE VERSUS LONG-ACTING LIPOSOMAL BUPIVACAINE Richard Knight, Paul Walker, Kirk Keegan, Stephen Overholser, Timothy Baumgartner, James Ebertowski, James Aden, and Michael White Richard KnightRichard Knight More articles by this author , Paul WalkerPaul Walker More articles by this author , Kirk KeeganKirk Keegan More articles by this author , Stephen OverholserStephen Overholser More articles by this author , Timothy BaumgartnerTimothy Baumgartner More articles by this author , James EbertowskiJames Ebertowski More articles by this author , James AdenJames Aden More articles by this author , and Michael WhiteMichael White More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1439AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Liposomal bupivacaine is a delayed-release preparation providing up to 72 hours of local analgesia. However, it costs much more than standard bupivacaine. A prospective, randomized, patient-blinded, controlled trial was performed to assess the efficacy of liposomal bupivacaine versus 0.25% bupivacaine when injected into surgical incisions during laparoscopic and robotic urologic surgery. METHODS A total of 206 adults were randomized to receive liposomal bupivacaine or 0.25% bupivacaine. All surgical incisions were injected with liposomal bupivacaine or 0.25% bupivacaine with systematic dosing. The primary outcome was total opioid consumption during the postoperative hospital stay. All opioid doses were converted to morphine equivalents. Secondary endpoints included pain scores using visual analog pain scales, duration of hospital stay, and the time to first opioid use. A subgroup analysis was performed for renal surgery patients. RESULTS There was no significant difference in mean total opioid use during the hospital stay between those who received liposomal bupivacaine (20.3 ± 18.5 mg) and 0.25% bupivacaine (24.1 ± 28.5 mg) (p = 0.39). Furthermore, pain scores, length of hospital stay, and time to first opioid use did not differ between groups. Subgroup analysis of laparoscopic renal surgery revealed no difference between liposomal bupivacaine and 0.25% bupivacaine. CONCLUSIONS For laparoscopic and robotic urologic surgery, there is no significant difference between liposomal bupivacaine and 0.25% bupivacaine for local analgesia at the incision sites. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e475 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Richard Knight More articles by this author Paul Walker More articles by this author Kirk Keegan More articles by this author Stephen Overholser More articles by this author Timothy Baumgartner More articles by this author James Ebertowski More articles by this author James Aden More articles by this author Michael White More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...